Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04553835
Other study ID # HSEARS20200630002
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 31, 2020
Est. completion date December 31, 2022

Study information

Verified date May 2022
Source The Hong Kong Polytechnic University
Contact Shu-Mei Wang, PhD
Phone 852-27664197
Email shumei.wang@polyu.edu.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research is to examine effects of movement training with the aid of rhythmic auditory stimulation (RAS) on reducing severity of dyskinesia and bradykinesia in at-risk individuals and schizophrenia patients. The investigators hypothesize that training with the aid of RAS reduced severity of bradykinesia and dyskinesia in at-risk individuals as well as in schizophrenia patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 13 Years to 65 Years
Eligibility For at-risk individuals: The inclusion criteria for at-risk individuals are: 1. A score of or above 9 in the Chinese version of the 16-item Prodromal Questionnaire (CPQ-16), or a score of or above 8.18 in the Chinese version of Community Assessment of Psychic Experiences with 15 items (CAPE-C15), or a score of or above 17 in Schizotypal Personality Questionnaire-Brief (SPQ-B); 2. A score of or above 22 in the Hong Kong version of Montreal Cognitive Assessment (HK-MoCA) to ensure that they can understand instructions; 3. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory to ensure that they are right-handed. 4. The age = 13 years. The inclusion criteria for healthy controls are: 1. A score below the cut-off score of CPQ-16, CAPE-C15, and SPQ-B; 2. A score of or above 22 in MoCA; 3. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory; 4. No first-degree family members having a diagnosis of mental illnesses. 5. The age = 13 years. At-risk participants and healthy controls will be excluded if they have any neurological / musculoskeletal dysfunction that may affect their upper-limb movements. For schizophrenia patients: The inclusion criteria for schizophrenia patients are: 1. A diagnosis of schizophrenia without other psychiatric diseases; 2. Having stable psychotic symptoms; 3. A score of or above 22 in HK-MoCA; 4. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory. 5. The age = 18 years. The inclusion criteria for healthy controls are: 1. A score below the cut-off score of CPQ-16, CAPE-C15, and SPQ-B; 2. A score of or above 22 in MoCA; 3. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory; 4. No first-degree family members having a diagnosis of mental illnesses. 5. The age = 18 years. Patients and healthy controls will be excluded if they have any neurological / musculoskeletal dysfunction that may affect their upper-limb movements.

Study Design


Intervention

Behavioral:
Rhythmic auditory stimulation (RAS) for schizophrenia patients
A mobile application, "metronome beats" developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Schizophrenia patients in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on the weekday basis (a total of 15 sessions) with one session (40 minutes) per weekday.
No RAS for schizophrenia patients
The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
RAS for at-risk individuals
A mobile application, "metronome beats" developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. At-risk individuals in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on daily basis (a total of 21 sessions), with one training session (40 minutes) per day.
No RAS for at-risk individuals
The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.

Locations

Country Name City State
Hong Kong Hong Kong Polytechnic University Kowloon

Sponsors (1)

Lead Sponsor Collaborator
Dr WANG Shumei

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK) normalized movement time (representing severity of parkinsonism). Unit: second/mm Within one week right before the 1st session of the intervention
Primary Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK) normalized movement time (representing severity of parkinsonism). Unit: second/mm Within one week right after the last session of the intervention
Primary Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK) normalized number of movement units (representing severity of dyskinesia). Unit: units/mm Within one week right before the 1st session of the intervention
Primary Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK) normalized number of movement units (representing severity of dyskinesia). Unit: units/mm Within one week right after the last session of the intervention
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A